Semaglutide In 2027 Medicare Price Negotiations; Most Other Drugs Lose Exclusivity By Then
15 Products Totaled $41bn In Annual Part D Spending
Novo took the biggest stock price hit of all the drug makers with products subject to Medicare price negotiations in 2027 under the IRA, but at least 11 of its peers on the list will be subject to generic competition between 2025 and 2027.
